Shanghai, China

Mao Bi

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 10(Granted Patents)


Company Filing History:


Years Active: 2018-2024

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Mao Bi: Innovator in Cancer Treatment

Introduction

Mao Bi is a notable inventor based in Shanghai, China, recognized for his significant contributions to the field of cancer treatment. With a total of four patents to his name, Bi has been instrumental in advancing therapeutic techniques through innovative approaches.

Latest Patents

Among his latest patents is a groundbreaking invention concerning the use of chimeric antigen receptor (CAR) modified cells to treat cancer. This patent describes compositions, methods, and kits designed to utilize CAR modified cells effectively in battling cancer. Notably, the innovation includes an isolated nucleic acid sequence encoding for CAR, which integrates several essential components: an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. The antigen binding domain is specifically designed to target antigens found in non-essential organs, highlighting the potential of CAR technology in precision oncological therapies.

Career Highlights

Mao Bi's career has flourished at Innovative Cellular Therapeutics Co., Ltd. and Innovative Cellular Therapeutics Holdings, Ltd. His role in these companies has enabled him to significantly contribute to research and development in cellular therapies aimed at improving cancer treatment methodologies.

Collaborations

Throughout his career, Bi has collaborated with distinguished colleagues, including Zhao Wu and Chengfei Pu. These partnerships have fostered an environment of innovation, pushing the boundaries of current cancer treatment techniques and enhancing therapeutic efficacy through collaborative efforts.

Conclusion

Mao Bi represents a vital force in the realm of innovative cancer therapies. His commitment to utilizing cutting-edge technology, particularly through the application of chimeric antigen receptor cells, paves the way for future advancements in the treatment of cancer. With a robust patent portfolio and fruitful collaborations, Bi continues to inspire the field of medical research and innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…